SVB Leerink Maintains Market Perform on Blueprint Medicines, Lowers Price Target to $56

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.

SVB Leerink analyst Andrew Berens maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Perform and lowers the price target from $60 to $56.

Total
0
Shares
Related Posts